Enhanced computed tomography or magnetic resonance imaging: A choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?

Acta Radiologica

Volumn 48, Issue 6, 2007, Pages 593-596

  Thomsen, H S ^a,b   Marckmann, P ^a   Logager, V B ^a  

^a Mental Health Services CPH   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM PENTETATE;

CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONTRAINDICATION; EDITORIAL; FEMALE; HUMAN; IMAGE ENHANCEMENT; KIDNEY DISEASE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; SYSTEMIC SCLEROSIS;

CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; RISK FACTORS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547375990     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850701370717     Document Type: Editorial

References (22)

1. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
2. Broome DR, Girguis M, Baron P, Cottrel A, Kjellin I, Kirk G. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 2007;188:586-92.
3. Center for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents -St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 2007;56:137-41.
4. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. J Am Soc Nephrol 2007:Epub.
5. Dharnidharka VR, Wesson SK, Fennell RS. Gadolinium and nephrogenic fibrosing dermopathy in pédiatric patients. Pediatr Nephrol 2006:Epub.
6. EMEA Decision, February 7, 2007. Available at URL: www.esur.org. Accessed: March 14, 2007.
7. Evenepoel P, Zeegers M, Segaert S, Claes K, Kuypers D, Maes B, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004;49:469-73.
8. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
9. High W, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:27-30.
10. Idée J-M, Port M, Raynal I, Schaefer, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-76.
11. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic systemic fibrosis. A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007;42:139-45.
12. Maloo M, Abt P, Kashyap R, Younan D, Zand M, Orloff M, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transpl 2006;6:2212-7.
13. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62.
14. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007:Epub.
15. Roditi G, Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine A, et al. A retrospective case-control study of gadolinium-enhanced magnetic resonance imaging and nephrogenic systemic fibrosis in patients with renal failure. ECR'07; B-100.
16. Sadowski E, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-57.
17. Thomsen HS. Current evidence on prevention and management of contrast induced nephropathy. Eur Radiol 2007:in press.
18. Thomsen HS. Extracellular gadolinium agents: latest evidence in tolerance and complications. ECR'07; A-384.
19. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006;16:2619-21.
20. Thomsen HS, Almén T, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology. Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 2002;12:2600-5.
21. Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serumcreatinine be measured before contrast medium administration? Eur Radiol 2005; 15:749-54.
22. Yerram P, Saab G, Karuparthi PR, Hayden M, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. J Am Soc Nephrol 2007:Epub.